Free Trial

Alphatec Q4 2024 Earnings Report

Alphatec logo
$10.01 -0.20 (-2.00%)
As of 03:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alphatec EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.19
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Alphatec Revenue Results

Actual Revenue
$176.79 million
Expected Revenue
$172.74 million
Beat/Miss
Beat by +$4.05 million
YoY Revenue Growth
N/A

Alphatec Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Remove Ads

Alphatec Earnings Headlines

Barclays Keeps Their Buy Rating on Alphatec Holdings (ATEC)
Trump Makes Major Crypto Announcement
Trump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.
See More Alphatec Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alphatec? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alphatec and other key companies, straight to your email.

About Alphatec

Alphatec (NASDAQ:ATEC), a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

View Alphatec Profile

More Earnings Resources from MarketBeat